Oral vasodilator therapy in patients with moderate to severe portopulmonary hypertension as a bridge to liver transplantation

European Journal of Gastroenterology and Hepatology

Volumn 25, Issue 4, 2013, Pages 495-502

  Raevens, Sarah ^a   De Pauw, Michel ^b   Reyntjens, Koen ^b   Geerts, Anja ^a   Verhelst, Xavier ^a   Berrevoet, Frederik ^a   Rogiers, Xavier ^a   Troisi, Roberto I ^a   Van Vlierberghe, Hans ^a   Colle, Isabelle ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b Department of Cardiology ^*  (Belgium)

Author keywords

liver transplantation; portopulmonary hypertension; vasodilator agents

Indexed keywords

AMBRISENTAN; BOSENTAN; DIURETIC AGENT; FUROSEMIDE; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; ILOPROST; MILRINONE; NITRIC OXIDE; PROSTACYCLIN; SILDENAFIL;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DIURETIC THERAPY; DOPPLER ECHOCARDIOGRAPHY; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; FEMALE; FUNCTIONAL STATUS; GASTROINTESTINAL SYMPTOM; HEART CATHETERIZATION; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LUNG ARTERY PRESSURE; MALE; MONOTHERAPY; MORTALITY; PORTOPULMONARY HYPERTENSION; PRIORITY JOURNAL; TOXIC HEPATITIS; TRANSTHORACIC ECHOCARDIOGRAPHY;

ADMINISTRATION, ORAL; ADULT; ANTIHYPERTENSIVE AGENTS; COMBINED MODALITY THERAPY; EXERCISE TEST; FEMALE; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PHENYLPROPIONATES; PHOSPHODIESTERASE 5 INHIBITORS; PYRIDAZINES; SULFONAMIDES; VASODILATOR AGENTS;

EID: 84875212687     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32835c504b     Document Type: Article

References (27)

1. Pilatis ND, Jacobs LE, Rerkpattanapipat P, Kotler MN, Owen A, Manzarbeitia C, et al. Clinical predictors of pulmonary hypertension in patients undergoing liver transplant evaluation. Liver Transpl 2000; 6:85-91.
2. Swanson KL, Krowka MJ. Screen for portopulmonary hypertension, especially in liver transplant candidates. Cleve Clin J Med 2008; 75: 121-130.
3. Stauber RE, Olschewski H. Portopulmonary hypertension: short review. Eur J Gastroenterol Hepatol 2010; 22:385-390.
4. Singh C, Sager JS. Pulmonary complications of cirrhosis. Med Clin North Am 2009; 93:871-883, viii.
5. Park MH. Advances in diagnosis and treatment in patients with pulmonary arterial hypertension. Catheter Cardiovasc Interv 2008; 71:205-213.
6. Colle I, Van SC, Geerts A, Van VH. Hepatopulmonary syndrome and portopulmonary hypertension: what's new? Acta Gastroenterol Belg 2007; 70:203-209.
7. Huffmyer JL, Nemergut EC. Respiratory dysfunction and pulmonary disease in cirrhosis and other hepatic disorders. Respir Care 2007; 52:1030-1036.
8. Ramsay M. Portopulmonary hypertension and right heart failure in patients with cirrhosis. Curr Opin Anaesthesiol 2010; 23:145-150.
9. Bozbas SS, Eyuboglu FO, Arslan NG, Ergur FO, Karakayali H, Haberal M. The prevalence and the impact of portopulmonary hypertension on postoperative course in patients undergoing liver transplantation. Transplant Proc 2009; 41:2860-2863.
10. Le PJ, Souza R, Herve P, Lebrec D, Savale L, Tcherakian C, et al. Portopulmonary hypertension: survival and prognostic factors. Am J Respir Crit Care Med 2008; 178:637-643.
11. Ashfaq M, Chinnakotla S, Rogers L, Ausloos K, Saadeh S, Klintmalm GB, et al. The impact of treatment of portopulmonary hypertension on survival following liver transplantation. Am J Transplant 2007; 7:1258-1264.
12. Colle IO, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen-Solal A, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology 2003; 37:401-409.
13. Austin MJ, McDougall NI, Wendon JA, Sizer E, Knisely AS, Rela M, et al. Safety and efficacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension. Liver Transpl 2008; 14:287-291.
14. Swanson KL. Treatment of portopulmonary hypertension-isn't it time to move forward? Liver Transpl 2008; 14:270-271.
15. Cartin-Ceba R, Swanson K, Iyer V, Wiesner RH, Krowka MJ. Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension. Chest 2011; 139:109-114.
16. Savale L, Magnier R, Le PJ, Jais X, Montani D, O'Callaghan DS, et al. Efficacy, safety, and pharmacokinetics of bosentan in portopulmonary hypertension. Eur Respir J 2012 [Epub ahead of print].
17. Hollatz TJ, Musat A, Westphal S, Decker C, D'Alessandro AM, Keevil J, et al. Treatment with sildenafil and treprostinil allows successful liver transplantation of patients with moderate to severe portopulmonary hypertension. Liver Transpl 2012; 18:686-695.
18. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982; 14:377-381.
19. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166:111-117.
20. Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000; 6:443-450.
21. Tam NL, He XS. Clinical management of portopulmonary hypertension. Hepatobiliary Pancreat Dis Int 2007; 6:464-469.
22. Benza RL, Park MH, Keogh A, Girgis RE. Management of pulmonary arterial hypertension with a focus on combination therapies. J Heart Lung Transplant 2007; 26:437-446.
23. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358:1119-1123.
24. Clift PF, Townend JN, Bramhall S, Isaac JL. Successful treatment of severe portopulmonary hypertension after liver transplantation by bosentan. Transplantation 2004; 77:1774-1775.
25. Reichen J, Gerbes AL, Steiner MJ, Sagesser H, Clozel M. The effect of endothelin and its antagonist bosentan on hemodynamics and microvascular exchange in cirrhotic rat liver. J Hepatol 1998; 28:1020-1030.
26. Findlay JY, Harrison BA, Plevak DJ, Krowka MJ. Inhaled nitric oxide reduces pulmonary artery pressures in portopulmonary hypertension. Liver Transpl Surg 1999; 5:381-387.
27. Roberts DH, Lepore JJ, Maroo A, Semigran MJ, Ginns LC. Oxygen therapy improves cardiac index and pulmonary vascular resistance in patients with pulmonary hypertension. Chest 2001; 120:1547-1555.